Synonyms: compound 3 [PMID: 31265286] | Example 1 [WO2014043446A1] | GSK2983559
Compound class:
Synthetic organic
Comment: This is an orally active RIPK2 inhibitor phosphate ester prodrug [1-2]. It is rapidly cleaved by alkaline phosphatases on contact with intestinal tissue and in whole blood. The prodrug formulation was designed to limit systemic exposure, and to focus activity at the preferred site of action in gut tissue.
A crystal structure of RIPK2 in complex with inhibitor 3 has been submitted to the PDB with ID 6RN8. |
|
No information available. |
Summary of Clinical Use |
This compound has been progressed to Phase 1 clinical evaluation for inflammatory bowel diseases (see NCT03358407). The research code used for the compound in this study is GSK2983559. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT03358407 | GSK2983559 First Time in Human Study | Phase 1 Interventional | GlaxoSmithKline |